RNA Therapeutics Conference and Focus Day

SMi Group 19 - 20 February 2020, London, UK.
The field of RNA therapeutics is rapidly expanding, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

The event will focus on the latest research and developments on delivery system technologies that aim to tackle more difficult targets within the human body. This overarching topic warrants high focus and therefore, for the first time in the series, introduce a focus day on Oligonucletide Delivery Systems. The main conference will focus on current developments in the area of mRNA therapeutics in immunotherapy and vaccination.

New for 2020: RNA Therapeutics Focus Day - Oligonucleotide Delivery Systems

18 February 2020, London, UK.
Introducing the only RNA therapeutics conference to hold a full day exploring alternatives to oligonucleotide delivery systems. The global antisense and RNA therapeutics market is expected to expand at a compound annual growth rate (CAGR) of 8.6% between 2019 and 2025, projected to reach $1.81 billion, this focus day will assess the growing need for research and development of novel delivery approaches to expand the current delivery methods in today's market.

How will you benefit?

  • Discuss the innovations in oligonucleotide delivery systems
  • Explore the latest developments in RNA delivery agents and RNA-based therapeutics
  • Learn from case studies on clinical developments with leading RNA therapeutics companies and regulatory bodies
  • Revisit the challenges for clinical translation of RNA-based therapeutics
  • Evaluate the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing
  • Gain an expert view on new and upcoming regulatory updates and industry implications

Network and learn from leading professionals such as:

Chair for 2020

Heinrich Haas, VP RNA Formulation and Drug Delivery,BioNTech

Featured speakers include

  • Shalini Andersson, Chief Scientist New Therapeutic Modalities,AstraZeneca
  • Christian Plank, CTO, Ethris
  • Steve Pascolo, Founder and CEO, Miescher Pharma
  • Kirsty Wydenbach, Deputy Unit Manager, Clinical Trials Unit, MhRA
  • Steven Powell, CEO, eTheRNA
  • Simon Newman, CSO, Nanogenics
  • Christiane Niederlaender, Director, AMBR Consulting and Formerly,
  • Quality Assessor, Biologicals, MhRA
  • Klaus Giese, CEO, Pantherna Therapeutics
  • David Blakey, CSO, MiNA Therapeutics
  • Jeffrey Ulmer, Head Preclinical R&D, GSK

For more information and to register, please visit:
http://www.therapeutics-rna.com/worldpharmanews

Early-Bird Rates

Register by 31st October to save £400 Register by 29th November to save £200 Register by 29th December to save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...